Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Болезнь Крона: современные аспекты антицитокиновой терапии
Болезнь Крона: современные аспекты антицитокиновой терапии
Ахмедов В.А., Орлов И.Н., Гаус О.В. Болезнь Крона: современные аспекты антицитокиновой терапии. Consilium Medicum. 2016; 18 (12): 96–99. DOI: 10.26442/2075-1753_2016.12.96-99
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Представлен обзор литературы по актуальным вопросам в лечении воспалительных заболеваний кишечника, в частности, болезни Крона. За основу взяты результаты рандомизированных исследований, проведенных в последние 10 лет. Рассмотрены такие термины, как «ускользание эффекта» и его причины, переход с одного антицитокинового препарата на другой при неэффективности первого и наличии ответа на него.
Ключевые слова: болезнь Крона, фактор некроза опухоли α, инфликсимаб, адалимумаб, рандомизированное исследование.
Ключевые слова: болезнь Крона, фактор некроза опухоли α, инфликсимаб, адалимумаб, рандомизированное исследование.
________________________________________________
A review of literature on topical issues in the treatment of inflammatory bowel diseases, such as Crohn's disease. It is based on the results of randomized studies conducted in the last 10 years. Considered terms such as “escape effect” and its causes, the transition from one anticytokine drug to another with the ineffectiveness of the first and the presence of the answer to it.
Key words: Crohn's disease, tumor necrosis factor α, infliximab, adalimumab, randomized study.
Key words: Crohn's disease, tumor necrosis factor α, infliximab, adalimumab, randomized study.
Полный текст
Список литературы
1. Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. М: Миклош, 2008. / Vorob'ev G.I., Khalif I.L. Nespetsificheskie vospalitel'nye zabolevaniia kishechnika. M: Miklosh, 2008. [in Russian]
2. Sartor RB. Pathogenesis ad immune mechanisms of chronic inflammatory bowel disease. Am J Gastroenterol 1997; 92 (Suppl. 12): 533–89.
3. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8: 171–8.
4. Breese E, Michie C, Nicholls S et al. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106; 1455–66.
5. Ассоциация колопроктологов России. Российская группа по изучению воспалительных заболеваний кишечника. Российские рекомендации по диагностике и лечению воспалительных заболеваний кишечника. М., 2012. / Assotsiatsiia koloproktologov Rossii. Rossiiskaia gruppa po izucheniiu vospalitel'nykh zabolevanii kishechnika. Rossiiskie rekomendatsii po diagnostike i lecheniiu vospalitel'nykh zabolevanii kishechnika. M., 2012. [in Russian]
6. Dignass A, Van Assche G, Lindsay JO et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohn’s Colitis 2010; 4 (1): 28–62.
7. Белоусова Е.А. Реальные и потенциальные возможности лечения рефрактерных форм воспалительных заболеваний кишечника. Рус. мед. журн. 2005; 2: 88–96. / Belousova E.A. Real'nye i potentsial'nye vozmozhnosti lecheniia refrakternykh form vospalitel'nykh zabolevanii kishechnika. Rus. med. zhurn. 2005; 2: 88–96. [in Russian]
8. Корниенко Е.А., Ломакина Е.А., Залетова Н.К., Фадина С.А. Возможности системных и топических стероидов в лечении воспалительных заболеваний кишечника у детей. Лечащий врач. 2010; 4: 82–5. / Kornienko E.A., Lomakina E.A., Zaletova N.K., Fadina S.A. Vozmozhnosti sistemnykh i topicheskikh steroidov v lechenii vospalitel'nykh zabolevanii kishechnika u detei. Lechashchii vrach. 2010; 4: 82–5. [in Russian]
9. Адлер Г. Болезнь Крона и язвенный колит. М.: ГЭОТАР-МЕД, 2001. / Adler G. Bolezn' Krona i iazvennyi kolit. M.: GEOTAR-MED, 2001. [in Russian]
10. Chey WY, Hussain A, Ryan C et al. Infliximab for refractory ulcerative colitis. Am Gastroenterol 2001; 96: 1860–6.
11. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2 (5): 379–88.
12. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s diseaseinadults. Am J Gastroenterol 2009; 104 (2): 465–83.
13. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009; 1: CD000067. DOI: 10.1002/14651858. CD000067.pub2.
14. Kaser A, Nieuwenhuis E, Glimcher L et al. Innate immunity in inflammatory bowel disease. Falk Symposium 2006; p. 23–4.
15. Российские рекомендации по диагностике и лечению воспалительных заболеваний кишечника. М., 2012. / Rossiiskie rekomendatsii po diagnostike i lecheniiu vospalitel'nykh zabolevanii kishechnika. M., 2012. [in Russian]
16. Travis S, Van Assche G, Dignass A et al. On the second ECCO Consensus on Crohn`s disease. J Crohn’s Colitis 2010; 4: 1–6.
17. Барановский А.Ю., Кондрашина Э.А., Харитонов А.Г. Прогноз неблагоприятного течения язвенного колита как показание к проведению антицитокиновой терапии. РЖГГК. 2012; 2; 63–9. / Baranovskiy A.Yu., Kondrashina E.A., Kharitonov A.G. Prognoz neblagopriiatnogo techeniia iazvennogo kolita kak pokazanie k provedeniiu antitsitokinovoi terapii. RZhGGK. 2012; 2; 63–9. [in Russian]
18. Валуйских Е.Ю., Светлова И.О., Курилович С.А. и др. Полиморфизм генов регуляторов воспаления при болезни Крона и неспецифическом язвенном колите. Бюллетень СО РАМН. 2009; 2 (136); 81–9. / Valuyskikh E.Yu., Svetlova I.O., Kurilovich S.A. et al. Polimorfizm genov reguliatorov vospaleniia pri bolezni Krona i nespetsificheskom iazvennom kolite. Biulleten' SO RAMN. 2009; 2 (136); 81–9. [in Russian]
19. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn’s disease. Am Fam Physician 2011; 84 (12): 1365–75.
20. Molnár T, Farkas K, Nyári T et al. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn’s disease after one-year treatment period – a single center experience. J Gastrointest Liver Dis 2012; 21 (3): 265–9.
21. Kestens C, van Oijen MG, Mulder CL et al. Dutch Initiative on Crohn and Colitis (ICC). Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti-tumor necrosis factor-a agents. Clin Gastroenterol Hepatol 2013; 11 (7): 826–31.
22. Etchevers MJ, Orda I, Richart E. Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohn’s Disease: A Practical Approach. Drugs 2010; 70: 109–20.
23. Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factorblockers for Crohn’s disease. World J Gastroenterol 2012; 18 (35): 4823–54.
24. Белоусова Е.А., Моисеев С.В. Инфликсимаб: 10 лет успешного применения при воспалительных заболеваниях кишечника. Клин. фармакология и терапия. 2010; 19 (1): 50–4. / Belousova E.A., Moiseev S.V. Infliksimab: 10 let uspeshnogo primeneniia pri vospalitel'nykh zabolevaniiakh kishechnika. Klin. farmakologiia i terapiia. 2010; 19 (1): 50–4. [in Russian]
25. Targan S, Hanauer S, van Deventer S et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. N Engl J Med 1997; 337: 1029–35.
26. Hanauer S, Feagan B, Lichtenstein G et al. Maintenance infliximab for Crohns disease: the ACCENT I randomized trial. Lancet 2002; 359 (9317): 1541–9.
27. Bruce E, Sands M, Frank H et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004; 350: 876–85.
28. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate to-severe Crohns disease in children. Clin Gastroenterol Hepatol 2012; 10 (4): 391–9.
29. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130 (2): 323–33.
30. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56 (9): 1232–9.
31. Zorzi F, Zuzzi S, Onali S et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther 2012; 35 (12): 1397–407.
32. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009; 104 (3): 760–7.
33. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011; 33 (9): 987–95.
34. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355–66.
35. De Ridder L, Rings EH, Damen GM et al. Infliximab dependency in pediatric Crohn’s disease: longterm follow-up of an unselected cohort. Inflamm Bowel Dis 2008; 14: 353–8.
36. Oussalah A, Babouri A, Chevaux JB et al. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year singlecentre experience. Aliment Pharmacol Ther 2009; 29 (4): 416–23.
37. Chaparro M, Andreu M, Barreiro-de Acosta M et al. Effectiveness of infliximab after adalimumab failure in Crohn’s disease. World J Gastroenterol 2012; 18 (37): 5219–24.
2. Sartor RB. Pathogenesis ad immune mechanisms of chronic inflammatory bowel disease. Am J Gastroenterol 1997; 92 (Suppl. 12): 533–89.
3. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8: 171–8.
4. Breese E, Michie C, Nicholls S et al. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106; 1455–66.
5. Assotsiatsiia koloproktologov Rossii. Rossiiskaia gruppa po izucheniiu vospalitel'nykh zabolevanii kishechnika. Rossiiskie rekomendatsii po diagnostike i lecheniiu vospalitel'nykh zabolevanii kishechnika. M., 2012. [in Russian]
6. Dignass A, Van Assche G, Lindsay JO et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohn’s Colitis 2010; 4 (1): 28–62.
7. Belousova E.A. Real'nye i potentsial'nye vozmozhnosti lecheniia refrakternykh form vospalitel'nykh zabolevanii kishechnika. Rus. med. zhurn. 2005; 2: 88–96. [in Russian]
8. Kornienko E.A., Lomakina E.A., Zaletova N.K., Fadina S.A. Vozmozhnosti sistemnykh i topicheskikh steroidov v lechenii vospalitel'nykh zabolevanii kishechnika u detei. Lechashchii vrach. 2010; 4: 82–5. [in Russian]
9. Adler G. Bolezn' Krona i iazvennyi kolit. M.: GEOTAR-MED, 2001. [in Russian]
10. Chey WY, Hussain A, Ryan C et al. Infliximab for refractory ulcerative colitis. Am Gastroenterol 2001; 96: 1860–6.
11. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2 (5): 379–88.
12. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s diseaseinadults. Am J Gastroenterol 2009; 104 (2): 465–83.
13. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009; 1: CD000067. DOI: 10.1002/14651858. CD000067.pub2.
14. Kaser A, Nieuwenhuis E, Glimcher L et al. Innate immunity in inflammatory bowel disease. Falk Symposium 2006; p. 23–4.
15. Rossiiskie rekomendatsii po diagnostike i lecheniiu vospalitel'nykh zabolevanii kishechnika. M., 2012. [in Russian]
16. Travis S, Van Assche G, Dignass A et al. On the second ECCO Consensus on Crohn`s disease. J Crohn’s Colitis 2010; 4: 1–6.
17. Baranovskiy A.Yu., Kondrashina E.A., Kharitonov A.G. Prognoz neblagopriiatnogo techeniia iazvennogo kolita kak pokazanie k provedeniiu antitsitokinovoi terapii. RZhGGK. 2012; 2; 63–9. [in Russian]
18. Valuyskikh E.Yu., Svetlova I.O., Kurilovich S.A. et al. Polimorfizm genov reguliatorov vospaleniia pri bolezni Krona i nespetsificheskom iazvennom kolite. Biulleten' SO RAMN. 2009; 2 (136); 81–9. [in Russian]
19. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn’s disease. Am Fam Physician 2011; 84 (12): 1365–75.
20. Molnár T, Farkas K, Nyári T et al. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn’s disease after one-year treatment period – a single center experience. J Gastrointest Liver Dis 2012; 21 (3): 265–9.
21. Kestens C, van Oijen MG, Mulder CL et al. Dutch Initiative on Crohn and Colitis (ICC). Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti-tumor necrosis factor-a agents. Clin Gastroenterol Hepatol 2013; 11 (7): 826–31.
22. Etchevers MJ, Orda I, Richart E. Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohn’s Disease: A Practical Approach. Drugs 2010; 70: 109–20.
23. Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factorblockers for Crohn’s disease. World J Gastroenterol 2012; 18 (35): 4823–54.
24. Belousova E.A., Moiseev S.V. Infliksimab: 10 let uspeshnogo primeneniia pri vospalitel'nykh zabolevaniiakh kishechnika. Klin. farmakologiia i terapiia. 2010; 19 (1): 50–4. [in Russian]
25. Targan S, Hanauer S, van Deventer S et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. N Engl J Med 1997; 337: 1029–35.
26. Hanauer S, Feagan B, Lichtenstein G et al. Maintenance infliximab for Crohns disease: the ACCENT I randomized trial. Lancet 2002; 359 (9317): 1541–9.
27. Bruce E, Sands M, Frank H et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004; 350: 876–85.
28. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate to-severe Crohns disease in children. Clin Gastroenterol Hepatol 2012; 10 (4): 391–9.
29. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130 (2): 323–33.
30. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56 (9): 1232–9.
31. Zorzi F, Zuzzi S, Onali S et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther 2012; 35 (12): 1397–407.
32. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009; 104 (3): 760–7.
33. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011; 33 (9): 987–95.
34. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355–66.
35. De Ridder L, Rings EH, Damen GM et al. Infliximab dependency in pediatric Crohn’s disease: longterm follow-up of an unselected cohort. Inflamm Bowel Dis 2008; 14: 353–8.
36. Oussalah A, Babouri A, Chevaux JB et al. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year singlecentre experience. Aliment Pharmacol Ther 2009; 29 (4): 416–23.
37. Chaparro M, Andreu M, Barreiro-de Acosta M et al. Effectiveness of infliximab after adalimumab failure in Crohn’s disease. World J Gastroenterol 2012; 18 (37): 5219–24.
2. Sartor RB. Pathogenesis ad immune mechanisms of chronic inflammatory bowel disease. Am J Gastroenterol 1997; 92 (Suppl. 12): 533–89.
3. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8: 171–8.
4. Breese E, Michie C, Nicholls S et al. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106; 1455–66.
5. Ассоциация колопроктологов России. Российская группа по изучению воспалительных заболеваний кишечника. Российские рекомендации по диагностике и лечению воспалительных заболеваний кишечника. М., 2012. / Assotsiatsiia koloproktologov Rossii. Rossiiskaia gruppa po izucheniiu vospalitel'nykh zabolevanii kishechnika. Rossiiskie rekomendatsii po diagnostike i lecheniiu vospalitel'nykh zabolevanii kishechnika. M., 2012. [in Russian]
6. Dignass A, Van Assche G, Lindsay JO et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohn’s Colitis 2010; 4 (1): 28–62.
7. Белоусова Е.А. Реальные и потенциальные возможности лечения рефрактерных форм воспалительных заболеваний кишечника. Рус. мед. журн. 2005; 2: 88–96. / Belousova E.A. Real'nye i potentsial'nye vozmozhnosti lecheniia refrakternykh form vospalitel'nykh zabolevanii kishechnika. Rus. med. zhurn. 2005; 2: 88–96. [in Russian]
8. Корниенко Е.А., Ломакина Е.А., Залетова Н.К., Фадина С.А. Возможности системных и топических стероидов в лечении воспалительных заболеваний кишечника у детей. Лечащий врач. 2010; 4: 82–5. / Kornienko E.A., Lomakina E.A., Zaletova N.K., Fadina S.A. Vozmozhnosti sistemnykh i topicheskikh steroidov v lechenii vospalitel'nykh zabolevanii kishechnika u detei. Lechashchii vrach. 2010; 4: 82–5. [in Russian]
9. Адлер Г. Болезнь Крона и язвенный колит. М.: ГЭОТАР-МЕД, 2001. / Adler G. Bolezn' Krona i iazvennyi kolit. M.: GEOTAR-MED, 2001. [in Russian]
10. Chey WY, Hussain A, Ryan C et al. Infliximab for refractory ulcerative colitis. Am Gastroenterol 2001; 96: 1860–6.
11. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2 (5): 379–88.
12. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s diseaseinadults. Am J Gastroenterol 2009; 104 (2): 465–83.
13. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009; 1: CD000067. DOI: 10.1002/14651858. CD000067.pub2.
14. Kaser A, Nieuwenhuis E, Glimcher L et al. Innate immunity in inflammatory bowel disease. Falk Symposium 2006; p. 23–4.
15. Российские рекомендации по диагностике и лечению воспалительных заболеваний кишечника. М., 2012. / Rossiiskie rekomendatsii po diagnostike i lecheniiu vospalitel'nykh zabolevanii kishechnika. M., 2012. [in Russian]
16. Travis S, Van Assche G, Dignass A et al. On the second ECCO Consensus on Crohn`s disease. J Crohn’s Colitis 2010; 4: 1–6.
17. Барановский А.Ю., Кондрашина Э.А., Харитонов А.Г. Прогноз неблагоприятного течения язвенного колита как показание к проведению антицитокиновой терапии. РЖГГК. 2012; 2; 63–9. / Baranovskiy A.Yu., Kondrashina E.A., Kharitonov A.G. Prognoz neblagopriiatnogo techeniia iazvennogo kolita kak pokazanie k provedeniiu antitsitokinovoi terapii. RZhGGK. 2012; 2; 63–9. [in Russian]
18. Валуйских Е.Ю., Светлова И.О., Курилович С.А. и др. Полиморфизм генов регуляторов воспаления при болезни Крона и неспецифическом язвенном колите. Бюллетень СО РАМН. 2009; 2 (136); 81–9. / Valuyskikh E.Yu., Svetlova I.O., Kurilovich S.A. et al. Polimorfizm genov reguliatorov vospaleniia pri bolezni Krona i nespetsificheskom iazvennom kolite. Biulleten' SO RAMN. 2009; 2 (136); 81–9. [in Russian]
19. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn’s disease. Am Fam Physician 2011; 84 (12): 1365–75.
20. Molnár T, Farkas K, Nyári T et al. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn’s disease after one-year treatment period – a single center experience. J Gastrointest Liver Dis 2012; 21 (3): 265–9.
21. Kestens C, van Oijen MG, Mulder CL et al. Dutch Initiative on Crohn and Colitis (ICC). Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti-tumor necrosis factor-a agents. Clin Gastroenterol Hepatol 2013; 11 (7): 826–31.
22. Etchevers MJ, Orda I, Richart E. Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohn’s Disease: A Practical Approach. Drugs 2010; 70: 109–20.
23. Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factorblockers for Crohn’s disease. World J Gastroenterol 2012; 18 (35): 4823–54.
24. Белоусова Е.А., Моисеев С.В. Инфликсимаб: 10 лет успешного применения при воспалительных заболеваниях кишечника. Клин. фармакология и терапия. 2010; 19 (1): 50–4. / Belousova E.A., Moiseev S.V. Infliksimab: 10 let uspeshnogo primeneniia pri vospalitel'nykh zabolevaniiakh kishechnika. Klin. farmakologiia i terapiia. 2010; 19 (1): 50–4. [in Russian]
25. Targan S, Hanauer S, van Deventer S et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. N Engl J Med 1997; 337: 1029–35.
26. Hanauer S, Feagan B, Lichtenstein G et al. Maintenance infliximab for Crohns disease: the ACCENT I randomized trial. Lancet 2002; 359 (9317): 1541–9.
27. Bruce E, Sands M, Frank H et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004; 350: 876–85.
28. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate to-severe Crohns disease in children. Clin Gastroenterol Hepatol 2012; 10 (4): 391–9.
29. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130 (2): 323–33.
30. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56 (9): 1232–9.
31. Zorzi F, Zuzzi S, Onali S et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther 2012; 35 (12): 1397–407.
32. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009; 104 (3): 760–7.
33. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011; 33 (9): 987–95.
34. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355–66.
35. De Ridder L, Rings EH, Damen GM et al. Infliximab dependency in pediatric Crohn’s disease: longterm follow-up of an unselected cohort. Inflamm Bowel Dis 2008; 14: 353–8.
36. Oussalah A, Babouri A, Chevaux JB et al. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year singlecentre experience. Aliment Pharmacol Ther 2009; 29 (4): 416–23.
37. Chaparro M, Andreu M, Barreiro-de Acosta M et al. Effectiveness of infliximab after adalimumab failure in Crohn’s disease. World J Gastroenterol 2012; 18 (37): 5219–24.
________________________________________________
2. Sartor RB. Pathogenesis ad immune mechanisms of chronic inflammatory bowel disease. Am J Gastroenterol 1997; 92 (Suppl. 12): 533–89.
3. Scaldaferri F, Fiocchi C. Inflammatory bowel disease: Progress and current concepts of etiopathogenesis. J Dig Dis 2007; 8: 171–8.
4. Breese E, Michie C, Nicholls S et al. Tumor necrosis factor alphaproducing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106; 1455–66.
5. Assotsiatsiia koloproktologov Rossii. Rossiiskaia gruppa po izucheniiu vospalitel'nykh zabolevanii kishechnika. Rossiiskie rekomendatsii po diagnostike i lecheniiu vospalitel'nykh zabolevanii kishechnika. M., 2012. [in Russian]
6. Dignass A, Van Assche G, Lindsay JO et al. European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Current management. J Crohn’s Colitis 2010; 4 (1): 28–62.
7. Belousova E.A. Real'nye i potentsial'nye vozmozhnosti lecheniia refrakternykh form vospalitel'nykh zabolevanii kishechnika. Rus. med. zhurn. 2005; 2: 88–96. [in Russian]
8. Kornienko E.A., Lomakina E.A., Zaletova N.K., Fadina S.A. Vozmozhnosti sistemnykh i topicheskikh steroidov v lechenii vospalitel'nykh zabolevanii kishechnika u detei. Lechashchii vrach. 2010; 4: 82–5. [in Russian]
9. Adler G. Bolezn' Krona i iazvennyi kolit. M.: GEOTAR-MED, 2001. [in Russian]
10. Chey WY, Hussain A, Ryan C et al. Infliximab for refractory ulcerative colitis. Am Gastroenterol 2001; 96: 1860–6.
11. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease. Clin Gastroenterol Hepatol 2004; 2 (5): 379–88.
12. Lichtenstein GR, Hanauer SB, Sandborn WJ. Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s diseaseinadults. Am J Gastroenterol 2009; 104 (2): 465–83.
13. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009; 1: CD000067. DOI: 10.1002/14651858. CD000067.pub2.
14. Kaser A, Nieuwenhuis E, Glimcher L et al. Innate immunity in inflammatory bowel disease. Falk Symposium 2006; p. 23–4.
15. Rossiiskie rekomendatsii po diagnostike i lecheniiu vospalitel'nykh zabolevanii kishechnika. M., 2012. [in Russian]
16. Travis S, Van Assche G, Dignass A et al. On the second ECCO Consensus on Crohn`s disease. J Crohn’s Colitis 2010; 4: 1–6.
17. Baranovskiy A.Yu., Kondrashina E.A., Kharitonov A.G. Prognoz neblagopriiatnogo techeniia iazvennogo kolita kak pokazanie k provedeniiu antitsitokinovoi terapii. RZhGGK. 2012; 2; 63–9. [in Russian]
18. Valuyskikh E.Yu., Svetlova I.O., Kurilovich S.A. et al. Polimorfizm genov reguliatorov vospaleniia pri bolezni Krona i nespetsificheskom iazvennom kolite. Biulleten' SO RAMN. 2009; 2 (136); 81–9. [in Russian]
19. Wilkins T, Jarvis K, Patel J. Diagnosis and management of Crohn’s disease. Am Fam Physician 2011; 84 (12): 1365–75.
20. Molnár T, Farkas K, Nyári T et al. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn’s disease after one-year treatment period – a single center experience. J Gastrointest Liver Dis 2012; 21 (3): 265–9.
21. Kestens C, van Oijen MG, Mulder CL et al. Dutch Initiative on Crohn and Colitis (ICC). Adalimumab and infliximab are equally effective for Crohn’s disease in patients not previously treated with anti-tumor necrosis factor-a agents. Clin Gastroenterol Hepatol 2013; 11 (7): 826–31.
22. Etchevers MJ, Orda I, Richart E. Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohn’s Disease: A Practical Approach. Drugs 2010; 70: 109–20.
23. Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factorblockers for Crohn’s disease. World J Gastroenterol 2012; 18 (35): 4823–54.
24. Belousova E.A., Moiseev S.V. Infliksimab: 10 let uspeshnogo primeneniia pri vospalitel'nykh zabolevaniiakh kishechnika. Klin. farmakologiia i terapiia. 2010; 19 (1): 50–4. [in Russian]
25. Targan S, Hanauer S, van Deventer S et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohns disease. N Engl J Med 1997; 337: 1029–35.
26. Hanauer S, Feagan B, Lichtenstein G et al. Maintenance infliximab for Crohns disease: the ACCENT I randomized trial. Lancet 2002; 359 (9317): 1541–9.
27. Bruce E, Sands M, Frank H et al. Infliximab maintenance therapy for fistulizing Crohns disease. N Engl J Med 2004; 350: 876–85.
28. Hyams J, Crandall W, Kugathasan S et al. Induction and maintenance infliximab therapy for the treatment of moderate to-severe Crohns disease in children. Clin Gastroenterol Hepatol 2012; 10 (4): 391–9.
29. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130 (2): 323–33.
30. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut 2007; 56 (9): 1232–9.
31. Zorzi F, Zuzzi S, Onali S et al. Efficacy and safety of infliximab and adalimumab in Crohn’s disease: a single centre study. Aliment Pharmacol Ther 2012; 35 (12): 1397–407.
32. Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol 2009; 104 (3): 760–7.
33. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther 2011; 33 (9): 987–95.
34. Allez M, Karmiris K, Louis E et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355–66.
35. De Ridder L, Rings EH, Damen GM et al. Infliximab dependency in pediatric Crohn’s disease: longterm follow-up of an unselected cohort. Inflamm Bowel Dis 2008; 14: 353–8.
36. Oussalah A, Babouri A, Chevaux JB et al. Adalimumab for Crohn’s disease with intolerance or lost response to infliximab: a 3-year singlecentre experience. Aliment Pharmacol Ther 2009; 29 (4): 416–23.
37. Chaparro M, Andreu M, Barreiro-de Acosta M et al. Effectiveness of infliximab after adalimumab failure in Crohn’s disease. World J Gastroenterol 2012; 18 (37): 5219–24.
Авторы
В.А.Ахмедов*, И.Н.Орлов, О.В.Гаус
ФГБОУ ВО Омский государственный медицинский университет Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12
*v_akhmedov@mail.ru
ФГБОУ ВО Омский государственный медицинский университет Минздрава России. 644099, Россия, Омск, ул. Ленина, д. 12
*v_akhmedov@mail.ru
________________________________________________
V.A.Akhmedov*, I.N.Orlov, O.V.Gaus
Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, d. 12
*v_akhmedov@mail.ru
Omsk State Medical University of the Ministry of Health of the Russian Federation. 644099, Russian Federation, Omsk, ul. Lenina, d. 12
*v_akhmedov@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.